Artemis Global Peer Comparison

NSE: AGLSL | BSE: 540616

₹49.45

₹-1.65 (-3.23%)

As on 23-Oct-2019IST

Market cap

₹327 Cr

Revenue (TTM)

₹556 Cr

P/E Ratio

15.5

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	327	34,725	27,559	26,684	27,197
Revenue (₹ Cr)	556	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	21.00	414.00	-371.81	288.22	387.35
Net Margin (%)	3.76	11.23	-3.93	14.79	26.01
RoE (%)	7.32	8.38	-3.85	29.77	25.18
Price to Earnings	15.51	84.90	--	92.58	70.42
Price-To-Book	1.41	6.90	3.44	19.88	15.76

Income Statement (₹ Cr)

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	546.52	3,565.84	--	153.79	238.51
Total Income	550.52	3,586.86	--	160.15	238.90
Total Expenditure	482.70	3,604.32	--	122.14	196.43
EBITDA	63.81	-38.48	--	31.65	42.08
Depreciation	20.07	163.95	--	8.26	2.60
EBIT	43.74	-202.43	--	23.39	39.48
Interest	11.00	265.14	--	2.61	4.75
Other Income	4.00	21.02	--	6.36	0.38
Exceptional Items	-0.11	-358.19	--	--	--
Profit before Tax	36.74	-446.55	--	27.14	35.11
Provision for Tax	16.36	-134.76	--	8.71	11.82
Profit after Tax	20.39	-311.79	--	18.43	23.30

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	293.46	2,674.80	--	196.86	82.22
Minority Interest	-0.07	329.83	--	--	--
Non-Current Liabilities	84.26	1,702.75	--	30.75	25.37
Current Liabilities	176.69	2,863.66	--	68.83	105.56
Total Liabilities	554.34	7,813.24	--	296.44	213.15

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	441.81	4,756.39	--	131.06	85.41
Current Assets	112.53	2,814.65	--	165.38	124.10
Total Assets	554.34	7,813.24	--	296.44	213.15
Total Debt*	114.18	3,374.60	--	49.52	53.91
Net Current Assets	-64.16	-49.01	--	96.56	18.54
Contingent Liabilities	7.86	473.19	--	0.48	0.08

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	40.45	183.32	--	-13.77	14.84
Cash Flow from Investing Activities	-49.52	94.57	--	4.25	-20.87
Cash from Financing Activities	14.37	-776.45	--	16.43	5.62
Net Cash Inflow / Outflow	5.30	-498.56	--	6.91	-0.41

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	14.91	-2.87	--	13.09	34.33
ROE (%)	9.36	-11.43	--	9.82	34.64
ROA (%)	3.88	-4.01	--	7.04	12.64
EBIT Margin (%)	12.41	-0.49	--	24.71	17.80
Net Margin (%)	3.70	-8.69	--	11.51	9.75
Cash Profit Margin (%)	7.40	-4.15	--	17.35	10.86

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	8.70	-9.43	--	135.95	26.72
EBIT Growth (%)	7.24	-114.30	--	326.10	26.85
Net Profit Growth (%)	-22.41	53.24	--	8,583.73	25.95
EPS Growth (%)	-22.01	68.03	--	8,583.73	25.51
Book Value Growth (%)	9.69	-6.14	--	10.33	40.52

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	19.64	0.00	--	0.00	0.00
Price / Book Value	1.77	1.86	--	0.00	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	7.44	-448.40	--	1.14	1.51
Market Cap (₹ Cr)	402.43	4,903.12	--	0.00	0.00

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.50	1.28	--	0.25	0.69
Short term debt to equity ratio	0.13	0.21	--	0.07	0.32
Current Ratio	0.64	0.98	--	2.40	1.18
Quick Ratio	0.60	0.70	--	2.12	0.81
Interest Coverage	4.34	-0.68	--	11.39	8.39

	Artemis Global	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	14.38	35.73	--	54.90	31.90
Asset Turnover	1.04	0.46	--	0.59	1.29
Receivable days	44.84	114.46	--	144.39	96.45
Inventory Days	4.47	85.73	--	39.59	50.55
Payable days	90.84	160.83	--	158.53	142.81
Cash Conversion Cycle	-41.53	39.36	--	25.45	4.19

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.